The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class.
Sofia
M J
MJ
Lilly Research Labs, Eli Lilly and Co., Indianapolis, IN 46285, USA.
Floreancig
P
P
Bach
N
N
Baker
S R
SR
Nelson
K
K
Sawyer
J S
JS
Baldwin
R
R
Cockerham
S L
SL
Fleisch
J H
JH
Froelich
L L
LL
Jackson
W T
WT
Marder
P
P
Roman
C R
CR
Saussy
D L
DL
Silbaugh
S A
SA
Spaethe
S M
SM
Stengel
P W
PW
D000284:Administration, Oral; D000818:Animals; D001565:Benzoates / Q000008:administration & dosage / Q000494:pharmacology*; D016084:Bronchoconstriction / Q000187:drug effects; D002462:Cell Membrane / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D007975:Leukotriene B4 / Q000494:pharmacology; D008168:Lung / Q000502:physiology*; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010636:Phenols / Q000494:pharmacology*; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013329:Structure-Activity Relationship
D001565:Benzoates; C094099:LY 293111; D010636:Phenols; D018102:Receptors, Leukotriene B4; D007975:Leukotriene B4